Physician profile
Marcy Baker
NPI 1922001825
$3,680.84
in general payments reported to CMS, 2019-2025
34 companies · $952 in 2025
The $952 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $154 · 2021: $188 · 2022: $347 · 2023: $897 · 2024: $404 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,254.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $856.53 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $377.96 | 2019-2025 | Bexsero, Penmenvy |
| Genentech USA, INC. | $370.11 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $338.12 | 2019-2023 | Jornay Pm |
| Pfizer INC. | $246.91 | 2019-2025 | |
| Cranial Technologies, INC | $149.33 | 2019-2024 | Doc Band |
| Modernatx, INC. | $147.55 | 2023 | Moderna Covid-19 Vaccine |
| Kaleo, INC. | $136.76 | 2019-2023 | Auvi-Q |
| Merck Sharp & Dohme LLC | $132.12 | 2019-2024 | Gardasil 9, Gardasil, Vaxelis |
| Sanofi Pasteur INC. | $121.84 | 2025 | |
| Sanofi-Aventis U.S. LLC | $74.65 | 2024-2025 | |
| Neos Therapeutics, Lp | $72.87 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Sobi, INC | $71.33 | 2019-2022 | |
| Abbott Laboratories | $62.32 | 2025 | Id Now Instrument, Id Now Strep A 2 |
| Astrazeneca Pharmaceuticals Lp | $59.98 | 2023-2024 | Flumist Quadrivalent |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cepheid | $49.81 | 2024 | Genexpert |
| Tris Pharma INC | $47.13 | 2019 | |
| Phadia US INC. | $46.90 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $38.38 | 2025 | Neffy |
| Collegium Pharmaceutical, INC. | $24.57 | 2025 | Jornay Pm |
| Novo Nordisk INC | $24.49 | 2023 | Wegovy |
| Verrica Pharmaceuticals INC. | $24.05 | 2025 | Ycanth |
| Adlon Therapeutics L.P. | $23.62 | 2020 | |
| Alk-Abello, INC | $23.59 | 2025 | Neffy, Grastek, Odactra |
| Kowa Pharmaceuticals America, INC. | $21.42 | 2025 | Zoryve |
| Qiagen, LLC | $20.08 | 2022 | |
| Mission Pharmacal Company | $16.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.03 | 2019 | |
| Vivus LLC | $14.78 | 2024 | Qsymia |
| Supernus Pharmaceuticals, INC. | $14.69 | 2025 | Qelbree |
| Galderma Laboratories, L.P. | $14.36 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $13.96 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcy Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.